Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.450
-0.030 (-2.03%)
At close: Oct 8, 2026, 4:00 PM EDT
1.520
+0.070 (4.83%)
After-hours: Oct 8, 2026, 7:30 PM EDT
Palisade Bio Revenue
Palisade Bio had revenue of $500.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $500.00K. That makes Palisade Bio the 44,511th largest company in the world by revenue and 6,342nd in the United States.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
505.38
Revenue / Employee
$35,714
Employees
14
Market Cap
252.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 61.21M |
| Sutro Biopharma | 45.70M |
| Zentalis Pharmaceuticals | 26.87M |
| AC Immune | 21.67M |
| Fate Therapeutics | 6.49M |
| Camp4 Therapeutics | 4.22M |
| Upstream Bio | 3.16M |
| Sol-Gel Technologies | 1.80M |
PALI News
- 7 hours ago - Palisade Bio initiated with an Outperform at Raymond James - TheFly
- 10 days ago - Palisade Bio to present clinical, translational data for PALI-2108 at UEG Week - TheFly
- 10 days ago - Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 - GlobeNewsWire
- 15 days ago - Palisade Bio Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 15 days ago - Palisade Bio expands Phase 2b Ascentra-UC with Health Canada CTA clearance - TheFly
- 15 days ago - Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance - GlobeNewsWire
- 16 days ago - Palisade Bio receives FDA clearance of IND for PALI-2108 - TheFly
- 16 days ago - Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD - GlobeNewsWire